Key Takeaways
- Gilead Sciences wrapped up its $7.8 billion Arcellx purchase on April 28, 2026, securing exclusive rights to anito-cel, a promising CAR T-cell treatment for multiple myeloma.
- The stock is testing support from an 11-year cup-shaped base with a breakout point at $123.47, while one market watcher sees potential upside to $173 by year-end — representing a 35% climb.
- Shares have slipped 8% this month but remain up 22% year-over-year, currently trading near $128.
- Technical indicators show GILD’s RSI at 27, the most oversold reading in over a year, with the 200-day moving average providing nearby support.
- The merger is forecast to impact 2026 GAAP and non-GAAP earnings per share by $5.57–$5.67, but analysts expect it to boost earnings starting in 2028 if regulatory approval is secured.
Gilead Sciences finalized its Arcellx takeover on April 28, offering $115 in cash per share alongside a conditional value right worth $5 per share. The transaction valued Arcellx’s equity at roughly $7.8 billion at the time of closure.
This transaction hands Gilead complete ownership of anitocabtagene autoleucel, commonly known as anito-cel, an experimental BCMA-targeted CAR T-cell treatment designed for multiple myeloma patients. Before this acquisition, the two companies worked together through a partnership involving Kite, Gilead’s cellular therapy division.
By acquiring Arcellx completely, Gilead removes the need for future profit-sharing arrangements, milestone payments, and royalty commitments. This strategic shift allows the pharmaceutical giant to accelerate development timelines and commercialization strategies.
The $5 contingent value right will only be distributed if anito-cel achieves at least $6 billion in cumulative worldwide sales from its market debut through the end of 2029. While this represents a challenging threshold, it signals strong belief in the therapy’s revenue-generating capabilities.
Cindy Perettie, who leads Gilead’s Kite division, emphasized that the organization is now concentrating on “executing with speed and discipline” as preparations advance to deliver anito-cel to patients. The Arcellx workforce and its proprietary D-Domain BCMA binder platform will be folded into Kite’s existing manufacturing capabilities and regulatory framework.
Financially, the acquisition is anticipated to decrease Gilead’s GAAP and non-GAAP diluted earnings per share for 2026 by $5.57 to $5.67. When excluding acquired in-process research and development costs, the deal is expected to slightly reduce earnings in 2026 and 2027, then contribute positively starting in 2028 — contingent upon anito-cel receiving FDA clearance.
Following the merger’s completion, Arcellx shares will no longer trade on the Nasdaq Global Select Market.
Chart Analysis
From a technical perspective, GILD has reached a compelling juncture. The shares are revisiting support from an 11-year cup-with-handle formation, with the critical pivot point sitting at $123.47 — a structure that formed following bearish price action in mid-2015.
Extended base patterns often demonstrate higher probability of success, making this support test particularly noteworthy for chart watchers. The stock’s relative strength index has fallen to 27, marking the lowest level observed in at least twelve months and suggesting severely oversold conditions. The 200-day moving average sits close by and previously provided support during May and October pullbacks last year.
GILD has posted losses in eight of the previous ten weeks, with April alone showing an 8% decline. Notably, the selling in both March and April occurred on below-average trading volume, which technical analysts often interpret as a positive signal indicating weak conviction among sellers.
Biotechnology Sector Dynamics
The SPDR S&P Biotech ETF has climbed 9% in 2026, outperforming the broader healthcare sector’s 7% decline, which currently ranks as the worst among the 11 primary S&P sectors. Meanwhile, the iShares Biotechnology ETF, which counts Gilead as its top holding at nearly 8% of total assets, has delivered less than 1% returns year-to-date.
GILD shares have advanced 4% since January and posted a 22% gain over the trailing twelve months despite recent weakness. One technical strategist has established a $173 year-end price objective, suggesting 35% appreciation potential from the current $128 level. The optimistic scenario remains intact provided shares hold above the $118 threshold.
Gilead completed its tender offer for Arcellx on April 28, with shareholders tendering approximately 77.2% of the company’s outstanding shares.
